Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
A new noninvasive risk score―incorporating factors such as waist circumference, age, sex, and histories of hyperglycaemia and diabetes in the family― reliably identifies those at high dysglycaemia risk, reports a new Saudi Arabia study.
Sleep disorder in nonstandard shift workers appears to contribute to more severe hypogonadal symptoms and lower testosterone levels when compared with daytime workers and nonstandard shift workers without sleep disorder, according to a study.
A US-based retrospective cohort study has shown no difference in the rates of mortality and cardiovascular disease (CVD) with initiation and continuous use of either analogue or human insulin in insulin-naïve adults with type 2 diabetes (T2D).
A high serum concentration of ferritin is a risk factor for type 2 diabetes, reports a new meta-analysis.
The risk of incident vertebral fractures (VFs) is lower among acromegaly patients with biochemically active disease treated with pasireotide LAR (Pasi) compared with those on pegvisomant (PegV), reports a recent study, which also confirms that the presence of pre-existent VFs is the main cause of incident VFs.
The inclusion of two proanthocyanidin (PA)-rich apples into normal diets improves cardiovascular disease (CVD) risk factors by reducing total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and intercellular cell adhesion molecule-1 (ICAM-1), as well as increasing microvascular vasodilation, in individuals with mildly elevated serum cholesterol concentrations, a recent study has shown.
An association exists between oncostatin M (OSM) and the inflammatory state during obesity, which may lead to the development of insulin resistance, reveals a study.
Special Reports
Saxagliptin 5 mg, dapagliflozin 10 mg FC tab
At a recent Boehringer Ingelheim-sponsored symposium held in conjunction with the 10th Malaysian Endocrine and Metabolic Society Annual Congress, two distinguished speakers spoke on the latest updates in glucose-lowering therapy for the treatment for type 2 diabetes mellitus (T2DM) and highlighted some important cardiovascular outcome trial results of these antidiabetic agents.
At the recent 10th Malaysian Endocrine and Metabolic Society (MEMS) Annual Congress(MAC) held in Hilton Kuala Lumpur, Dr Wong Ming, a consultant endocrinologist from Sunway Medical Centre, spoke on the role of non–high-density lipoprotein cholesterol (non–HDL-c) as an emerging marker and treatment target for cardiovascular (CV) disease. Additionally, she also highlighted the role of fenofibrate in delaying and preventing diabetic retinopathy (DR).
At a recent Abbott lunch symposium held in conjunction with the joint 12th International Diabetes FederationWestern Pacific Region Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in KualaLumpur, Professor Shashank R. Joshi extensively discussed the issue of diabetes in obesity and the role of nutritionalintervention in addressing this growing problem.
At the recent 12th IDF-WPR Congress and 10th AASD Scientific Meeting held at Kuala Lumpur Convention Centre, the importance of glycaemic control and the practical management of type 2 diabetes mellitus (T2DM) were highlighted by two international speakers, Dr Sanjay Kalra from India and Professor Jean Claude Mbanya from Cameroon.
Dapagliflozin 5 mg and 10 mg FC tab
At the Abbott-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congres sat Hilton Kuala Lumpur, Dr Zanariah Hussein shared her insights into the important role of an emerging marker of hypercholesterolaemia, and its relationship with cardiovascular (CV) and diabetic retinopathy (DR) risks.
Conference Reports
Multiple analyses of the DAPA-HF* trial have shown that dapagliflozin, in addition to standard therapy, reduces the risk of multiple heart failure (HF) outcomes including cardiovascular (CV) death and hospitalization for HF (HHF) in patients with HF and reduced ejection fraction (HFrEF), with the effects consistent regardless of age and type 2 diabetes (T2D) status.
Slideshow: Highlights from the American Heart Association (AHA) Scientific Sessions 2019
Podcast: Professor Carolyn Lam states that dapagliflozin appears to meet the three major aims of HFrEF treatment, ie, reduced mortality, reduced hospitalization, and improved quality of life.
Podcast: Professor John McMurray says that the DAPA-HF trial demonstrates the efficacy of dapagliflozin in reducing the risk of heart failure in patients with HFrEF with and without T2D.
Podcast: Professor R. Scott Wright speaks about the potential role of inclisiran in providing durable reductions in LDL-cholesterol levels in patients with atherosclerotic cardiovascular disease.
Upfront combination therapy with metformin and the DPP-4* inhibitor vildagliptin may improve glycaemic durability in patients newly diagnosed with type 2 diabetes (T2D) compared with sequential therapy with metformin monotherapy followed by vildagliptin, results from the VERIFY** trial showed.
The novel dual GIP* and GLP-1** receptor agonist tirzepatide demonstrated clinically meaningful improvements in glycaemic control and weight loss in patients with type 2 diabetes (T2D), according to data presented at EASD 2019.
Multimedia
